Austrianova and the Research Institute of Virology & Biomedicine granted retroviral patent in Europe
"We are extremely pleased that this technology has been deemed both novel and inventive" said Prof. Walter H. Günzburg, Head of the Research Institute and a co-inventor. ReCon allows the production of retroviral vectors carrying toxic or cytostatic genes from vector producing cells and thus circumvents a common problem encountered when using previous generations of retroviral vector.
The exclusive licensee of this technology is the Research Institute's partner, Austrianova. "We can apply these innovative vectors for the treatment of solid tumours in combination with therapeutic genes that can directly kill cancer cells" commented Brian Salmons, Managing Partner: Science and Technology, Austrianova.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.